SCHEMBL4334398

SCHEMBL4334398

Cc1cc(OCc2ccc(C=NN(C)C(N)=S)o2)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
TSHR P16473 1/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
MAPT P10636 5/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
HSP90AA1 P07900 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MCL1 Q07820 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
MAPK1 P28482 1/20 0.37
PKM P14618 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4332719 0.92 MAPT (0.39) POLBTSHRNPC1RAB9AMAPT
SCHEMBL4330786 0.82 ALDH1A1 (0.53) POLBTSHRNPC1RAB9AMAPT
SCHEMBL4330782 0.82 ALDH1A1 (0.53) POLBTSHRNPC1RAB9AMAPT
SCHEMBL13612377 0.78 MAPT (0.48) POLBTSHRNPC1RAB9AMAPT
SCHEMBL4334401 0.78 MAPT (0.48) POLBTSHRNPC1RAB9AMAPT
SCHEMBL4331630 0.75 MAPT (0.39) POLBTSHRNPC1RAB9AMAPT
SCHEMBL4326576 0.73 SMN1; SMN2 (0.39) POLBTSHRMAPTKMT2AMEN1
SCHEMBL4336892 0.72 ALDH1A1 (0.61) POLBMAPTKMT2AMEN1SMN1; SMN2
SCHEMBL4336889 0.72 ALDH1A1 (0.61) POLBMAPTKMT2AMEN1SMN1; SMN2
SCHEMBL6445038 0.71 KMT2A (0.63) POLBNPC1RAB9AMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 POLB 3179/4885TSHR 2969/4885NPC1 1680/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 POLB 3934/4885TSHR 2747/4885NPC1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.